Blood-brain barrier transport machineries and targeted therapy of brain diseases

BioImpacts - Tập 6 Số 4 - Trang 225-248
Jaleh Barar1, Mohammad A. Rafi2, Mohammad M. Pourseif3, Yadollah Omidi1
1Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran ; Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
2Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
3Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.5681/bi.2012.002

10.1007/978-1-61779-452-0_34

10.1038/nrn1824

10.1002/cbf.1455

10.1385/MB:30:1:057

10.1002/cpt.64

Begley DJ, 2004, ABC transporters and the blood-brain barrier, Curr Pharm Des, 10, 1295, 10.2174/1381612043384844

10.1038/jcbfm.2012.126

10.1007/s11095-007-9324-2

Wood MJ, 2011, Exosomes and the blood-brain barrier: implications for neurological diseases, Ther Deliv, 2, 1095, 10.4155/tde.11.83

10.15171/bi.2015.22

O’Loughlin AJ, 2012, Exosomes and the emerging field of exosome-based gene therapy, Curr Gene Ther, 12, 262, 10.2174/156652312802083594

10.1038/ncomms3123

10.1016/j.addr.2012.07.002

Gumbleton M, 2001, Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier, J Pharm Sci, 90, 1681, 10.1002/jps.1119

10.1080/10611860701288539

Barar J, 2010, Barrier functionality and transport machineries of human ECV304 cells, Med Sci Monit, 16, 52

10.5681/bi.2011.021

Omidi Y, 2003, Evaluation of the immortalised mouse brain capillary endothelial cell line, bEnd3, as an in vitro blood-brain barrier model for drug uptake and transport studies, Brain Res, 990, 95, 10.1016/S0006-8993(03)03443-7

10.1371/journal.pone.0152105

10.1177/0271678X16630991

Rapoport SI, 1978, Osmotic opening of the blood-brain barrier, Ciba Found Symp, 237

Easton AS, 2002, Bradykinin increases permeability by calcium and 5-lipoxygenase in the ECV304/C6 cell culture model of the blood-brain barrier, Brain Res, 953, 157, 10.1016/S0006-8993(02)03281-X

Sanovich E, 1995, Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7, Brain Res, 705, 125, 10.1016/0006-8993(95)01143-9

Abbott NJ, 2000, Inflammatory mediators and modulation of blood-brain barrier permeability, Cell Mol Neurobiol, 20, 131, 10.1023/A:1007074420772

10.1517/14728222.2015.1042364

10.1016/bs.apha.2014.06.001

10.2217/imt.09.75

10.1146/annurev.pharmtox.47.120505.105237

10.1016/j.biotechadv.2015.02.004

10.1021/acsnano.5b01872

10.1016/j.actbio.2013.11.003

10.3109/1061186X.2014.886038

10.1016/j.bbrc.2014.04.148

Ordovas JM, 2000, ABC1: the gene for Tangier disease and beyond, Nutr Rev, 58, 76, 10.1111/j.1753-4887.2000.tb01843.x

10.1167/iovs.14-14098

10.1074/jbc.M804505200

10.1038/ng.3246

10.1371/journal.pgen.1004333

10.1086/429844

10.1002/(SICI)1098-1004(200002)15:2>135::AIDHUMU2<3.0.CO;2-H

10.1016/j.eplepsyres.2005.12.005

10.1124/dmd.108.024018

10.1093/brain/awv250

10.3892/mmr.2014.2424

10.1016/j.ophtha.2014.04.027

10.1177/0269881113490329

10.1194/M900250-JLR200

Nicolazzo JA, 2009, Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2), Curr Top Med Chem, 9, 130, 10.2174/156802609787521580

10.1210/endo.132.1.8419132

Pardridge WM, 1990, Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier Studies with quantitative western blotting and in situ hybridization, J Biol Chem, 265, 18035, 10.1016/S0021-9258(18)38267-X

10.1002/cphy.c130008

Miller LP, 1986, Regional kinetic constants for blood-brain barrier pyruvic acid transport in conscious rats by the monocarboxylic acid carrier, J Neurochem, 46, 1412, 10.1111/j.1471-4159.1986.tb01756.x

Oldendorf WH, 1973, Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids, Am J Physiol, 224, 1450, 10.1152/ajplegacy.1973.224.6.1450

Conn AR, 1983, Characterization of alpha-keto acid transport across blood-brain barrier in rats, Am J Physiol, 245, E253

10.1210/en.2008-1616

Kido Y, 2001, Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier, J Pharm Pharmacol, 53, 497, 10.1211/0022357011775794

Kageyama T, 2000, The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier, Brain Res, 879, 115, 10.1016/S0006-8993(00)02758-X

10.4155/tde.12.165

10.3109/10611860008996865

O’Kane RL, 1999, Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier A mechanism for glutamate removal, J Biol Chem, 274, 31891, 10.1074/jbc.274.45.31891

Benrabh H, 1996, Glutamate is transported across the rat blood-brain barrier by a sodium-independent system, Neurosci Lett, 210, 9, 10.1016/0304-3940(96)12635-5

10.1152/ajpendo.00007.2006

Stoll J, 1993, Identification of the cationic amino acid transporter (System y+) of the rat blood-brain barrier, J Neurochem, 60, 1956, 10.1111/j.1471-4159.1993.tb13428.x

Benrabh H, 1995, Taurine transport at the blood-brain barrier: an in vivo brain perfusion study, Brain Res, 692, 57, 10.1016/0006-8993(95)00648-A

Tamai I, 1995, Na(+)- and Cl(-)-dependent transport of taurine at the blood-brain barrier, Biochem Pharmacol, 50, 1783, 10.1016/0006-2952(95)02046-2

Komura J, 1997, Brain-to-blood active transport of beta-alanine across the blood-brain barrier, FEBS Lett, 400, 131, 10.1016/S0014-5793(96)01366-X

Murakami H, 2000, Characteristics of choline transport across the blood-brain barrier in mice: correlation with in vitro data, Pharm Res, 17, 1526, 10.1023/A:1007613326759

Kang YS, 1990, In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood-brain barrier, J Pharmacobiodyn, 13, 353, 10.1248/bpb1978.13.353

Karlsson C, 1984, Choline transport through the blood-retinal and the blood-brain barrier in vivo, Acta Ophthalmol (Copenh), 62, 763, 10.1111/j.1755-3768.1984.tb05804.x

Masereeuw R, 1994, In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors, Pharm Res, 11, 324, 10.1023/A:1018932213953

Tsuji A, 1999, Organic anion transporters, Pharm Biotechnol, 12, 471, 10.1007/0-306-46812-3_16

Tsuji A, 1999, Carrier-mediated or specialized transport of drugs across the blood-brain barrier, Adv Drug Deliv Rev, 36, 277, 10.1016/S0169-409X(98)00084-2

Adkison KD, 1996, Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter, J Pharmacol Exp Ther, 276, 1189

Dick AP, 1984, Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity, Proc Natl Acad Sci U S A, 81, 7233, 10.1073/pnas.81.22.7233

10.1002/glia.440140107

Cornford EM, 2000, Acute upregulation of blood-brain barrier glucose transporter activity in seizures, Am J Physiol Heart Circ Physiol, 279, H1346, 10.1152/ajpheart.2000.279.3.H1346

10.3390/ijms131012629

10.1038/nn.3966

10.1038/ng0298-188

Humphrey W, 1996, VMD: visual molecular dynamics, J Mol Graph, 14, 33, 10.1016/0263-7855(96)00018-5

10.1002/iub.572

10.1074/jbc.M511397200

10.1007/s00424-009-0750-3

10.1186/1756-6614-4-S1-S7

10.1016/j.ygcen.2015.02.021

10.1371/journal.pone.0017416

10.18632/oncotarget.10114

10.5681/bi.2013.036

10.5681/bi.2014.021

Verrey F, 2000, Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity, Pflugers Arch, 440, 503, 10.1007/s004240000274

Wagner CA, 2000, The heterodimeric amino acid transporter 4F2hc/LAT1 is associated in Xenopus oocytes with a non-selective cation channel that is regulated by the serine/threonine kinase sgk-1, J Physiol, 526 Pt 1, 35, 10.1111/j.1469-7793.2000.00035.x

Broer A, 2001, Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires different domains, Biochem J, 355, 725, 10.1042/bj3550725

Wagner CA, 2001, Function and structure of heterodimeric amino acid transporters, Am J Physiol Cell Physiol, 281, C1077, 10.1152/ajpcell.2001.281.4.C1077

Hosoya K, 2002, Enhancement of L-cystine transport activity and its relation to xCT gene induction at the blood-brain barrier by diethyl maleate treatment, J Pharmacol Exp Ther, 302, 225, 10.1124/jpet.302.1.225

10.1007/s00424-002-0973-z

10.1038/ng1406

10.1002/iub.210

10.1046/j.1523-1755.1998.00956.x

10.1007/s00240-015-0794-0

Markazi S, 2016, A Novel Mutation in SLC3A1 Gene in Patients With Cystinuria, Iran J Kidney Dis, 10, 44

Matsuo H, 2000, Expression of a system L neutral amino acid transporter at the blood-brain barrier, Neuroreport, 11, 3507, 10.1097/00001756-200011090-00021

Nii T, 2001, Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation, Biochem J, 358, 693, 10.1042/bj3580693

Kim DK, 2002, Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells, Biochim Biophys Acta, 1565, 112, 10.1016/S0005-2736(02)00516-3

Kanai Y, 2003, Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity, J Toxicol Sci, 28, 1, 10.2131/jts.28.1

Boado RJ, 1999, Selective expression of the large neutral amino acid transporter at the blood-brain barrier, Proc Natl Acad Sci U S A, 96, 12079, 10.1073/pnas.96.21.12079

Meier C, 2002, Activation of system L heterodimeric amino acid exchangers by intracellular substrates, EMBO J, 21, 580, 10.1093/emboj/21.4.580

10.1210/endo.142.10.8418

Yanagida O, 2001, Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines, Biochim Biophys Acta, 1514, 291, 10.1016/S0005-2736(01)00384-4

Segawa H, 1999, Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity, J Biol Chem, 274, 19745, 10.1074/jbc.274.28.19745

10.1016/j.neulet.2008.01.028

Rossier G, 1999, LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine, J Biol Chem, 274, 34948, 10.1074/jbc.274.49.34948

10.1177/0271678X15609331

10.1002/cmdc.201402281

10.1021/mp2001878

10.1016/j.ejps.2008.06.015

10.1016/j.bcp.2010.05.021

10.3892/etm.2010.117

Kaira K, 2011, Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence, Anticancer Res, 31, 3775

Kaira K, 2015, Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer, Am J Transl Res, 7, 356

10.1021/acs.jmedchem.6b00190

10.1016/j.bbrc.2013.08.020

10.1038/leu.2014.338

10.1111/cas.12672

10.1016/j.ejps.2014.09.025

10.1002/humu.10140

10.1038/6809

10.1038/sj.ejhg.5201376

10.1002/jnr.22577

10.1038/jcbfm.2011.121

10.1007/s11011-014-9546-z

10.3945/ajcn.2009.27462BB

Broer S, 2001, Transfer of glutamine between astrocytes and neurons, J Neurochem, 77, 705, 10.1046/j.1471-4159.2001.00322.x

Omidi Y, Gumbleton M. Biological membranes and barriers. Biomaterials for Delivery and Targeting of Proteins Nucleic Acids, Mahato, RI (Ed): CRC Press, New York; 2005. p. 232-74.

Boleti H, 1997, Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells, Neuropharmacology, 36, 1167, 10.1016/S0028-3908(97)00136-6

10.1080/10611860410001731398

10.4155/fmc.12.79

10.1152/ajprenal.00215.2002

10.1111/j.1523-1755.2005.00444.x

10.1074/jbc.M007746200

Damaraju S, 2005, Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene, Pharmacogenet Genomics, 15, 173, 10.1097/01213011-200503000-00006

10.1124/dmd.112.049858

10.1016/j.ejps.2004.02.006

Balzarini J, 1998, Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection, J Acquir Immune Defic Syndr Hum Retrovirol, 17, 296, 10.1097/00042560-199804010-00002

Schinkel AH, 1999, P-Glycoprotein, a gatekeeper in the blood-brain barrier, Adv Drug Deliv Rev, 36, 179, 10.1016/S0169-409X(98)00085-4

10.1172/JCI70430

10.1172/JCI118214

10.3181/0802-RM-59

10.1002/ijc.26000

10.1292/jvms.14-0671

10.1111/epi.12158

10.1007/978-3-319-21756-7_12

Ganapathy V, 1991, Proton-coupled solute transport in the animal cell plasma membrane, Curr Opin Cell Biol, 3, 695, 10.1016/0955-0674(91)90043-X

10.1152/ajpcell.00093.2009

10.1007/s00424-013-1342-9

10.1152/ajpgi.00017.2011

10.1007/BF02788388

Zhou X, 2000, Characterization of an oligopeptide transporter in renal lysosomes, Biochim Biophys Acta, 1466, 372, 10.1016/S0005-2736(00)00201-7

Momburg F, 1994, Peptide selection by MHC-encoded TAP transporters, Curr Opin Immunol, 6, 32, 10.1016/0952-7915(94)90030-2

Roelse J, 1994, Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling, J Exp Med, 180, 1591, 10.1084/jem.180.5.1591

Tsuji A, 1999, Tissue selective drug delivery utilizing carrier-mediated transport systems, J Control Release, 62, 239, 10.1016/S0168-3659(99)00043-7

Zhang Y, 2013, Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance, Curr Drug Metab, 14, 675, 10.2174/1389200211314060004

10.1002/(SICI)1520-6017(200006)89:6>781::AIDJPS10<3.0.CO;2-7

10.1080/10611860600650086

10.1038/nrd2897

10.1080/10611860310001636908

Omidi Y, 2005, Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology, Curr Drug Deliv, 2, 429, 10.2174/156720105774370249

10.1080/15376510801891286

Nomani A, 2010, Physicochemical and biological properties of self-assembled antisense/poly(amidoamine) dendrimer nanoparticles: the effect of dendrimer generation and charge ratio, Int J Nanomedicine, 5, 359

10.5681/bi.2011.004

10.15171/bi.2016.07

Schlachetzki F, 2002, Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier, J Neurochem, 81, 203, 10.1046/j.1471-4159.2002.00840.x

Schnitzer JE, 1992, gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis, Am J Physiol, 262, H246

Vogel SM, 2001, Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein, Am J Physiol Lung Cell Mol Physiol, 281, L1512, 10.1152/ajplung.2001.281.6.L1512

10.1007/978-1-61779-191-8_26

10.1016/j.brainres.2013.08.035

10.4161/mabs.4.2.19397

Piper RC, 2001, Late endosomes: sorting and partitioning in multivesicular bodies, Traffic, 2, 612, 10.1034/j.1600-0854.2001.20904.x

Dice JF, 1992, Selective degradation of cytosolic proteins by lysosomes, Ann N Y Acad Sci, 674, 58, 10.1111/j.1749-6632.1992.tb27477.x

Luzio JP, 2005, Membrane traffic to and from lysosomes, Biochem Soc Symp, 77, 10.1042/bss0720077

Dice JF, 1990, Targeting of cytosolic proteins to lysosomes for degradation, Crit Rev Ther Drug Carrier Syst, 7, 211

Razani B, 2002, Caveolae: from cell biology to animal physiology, Pharmacol Rev, 54, 431, 10.1124/pr.54.3.431

Gumbleton M, 2001, Caveolae-mediated membrane transport, Adv Drug Deliv Rev, 49, 217, 10.1016/S0169-409X(01)00137-5

Gumbleton M, 2003, Targeting caveolae for vesicular drug transport, J Control Release, 87, 139, 10.1016/S0168-3659(02)00358-9

DeGrella RF, 1982, Intracellular transport of cholesterol to the plasma membrane, J Biol Chem, 257, 14256, 10.1016/S0021-9258(19)45374-X

Kaplan MR, 1985, Transport of cholesterol from the endoplasmic reticulum to the plasma membrane, J Cell Biol, 101, 446, 10.1083/jcb.101.2.446

10.1517/14728222.2015.1009446

10.1016/j.cllc.2015.05.004

10.1371/journal.pone.0086317

10.1007/s11095-014-1598-6

10.3762/bjnano.6.16

Popova NV, 2013, Clathrin-mediated endocytosis and adaptor proteins, Acta Naturae, 5, 62, 10.32607/20758251-2013-5-3-62-73

10.1083/jcb.201307100

10.1016/j.devcel.2015.03.002

10.1242/jcs.01668

10.1007/978-1-4939-2569-8_24

10.2217/nnm.15.29

10.3109/03639045.2013.861478

10.1016/j.ijpharm.2015.04.049

10.1186/1476-4598-13-191

10.1007/s10856-012-4658-7

10.1016/j.jconrel.2008.03.007

10.1021/bc050217o

10.1097/01.WCB.0000135592.28823.47

10.3109/1061186X.2015.1025077

10.1021/acs.molpharmaceut.5b00597

10.1016/j.biomaterials.2013.08.039

10.1016/j.biomaterials.2013.07.075

10.2217/nnm.11.98

10.4155/tde.13.38

10.1021/mp500238m

10.1073/pnas.1517048112

10.1021/acsnano.5b07573

10.1021/mp500057n

10.1016/j.ijpharm.2016.06.127

10.1039/c5bm00383k

10.1016/j.addr.2013.09.006